Clinical TrialJul 23, 2026, 04:13 PM
MacroGenics MGC026 Phase 1 results accepted for ESMO 2026
AI Summary
MacroGenics provided a clinical update on its ongoing Phase 1 study of MGC026, a B7-H3-directed antibody-drug conjugate. Interim results have been accepted for a poster presentation at the ESMO Congress 2026. The company met the pre-specified Stage 1 response threshold in the squamous cell carcinoma of the head and neck (SCCHN) cohort and is now enrolling Stage 2, with enrollment continuing in other tumor-specific cohorts. Additionally, results from a Phase 2 study of lorigerlimab will also be presented at ESMO.
Key Highlights
- MGC026 interim Phase 1 results accepted for poster presentation at ESMO Congress 2026.
- Achieved pre-specified Stage 1 response threshold in SCCHN cohort, now enrolling Stage 2.
- Ongoing enrollment in endometrial cancer, melanoma, and soft tissue sarcoma cohorts.
- Dose escalation completed in Q4 2025, with 7.5 mg/kg q3W dose being evaluated.
- 74 patients enrolled as of July 8, 2026, with no interstitial lung disease or ocular toxicity.
- Evidence of anti-tumor activity observed across several indications for MGC026.
- Phase 2 study results for lorigerlimab in gynecologic cancers also to be presented at ESMO.
Price Impact
More from MGNX